Maravai Lifesciences Holdings (MRVI) Depreciation & Amortization (CF) (2020 - 2026)

Maravai Lifesciences Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 13.93% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $22.8 million, a 4.59% increase from a year earlier, with the FY2025 full-year figure at $23.6 million, up 12.92% from the prior year.
• Depreciation & Amortization (CF) slipped to $4.9 million in Q1 2026 per MRVI's latest filing, from $6.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $6.0 million in Q3 2025 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $4.8 million (2024), against an average of $4.1 million.
• Across the five-year window, Depreciation & Amortization (CF) jumped 130.1% in 2024 and slipped 13.93% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.0 million in 2022, then surged by 97.09% to $3.9 million in 2023, then jumped by 40.16% to $5.5 million in 2024, then grew by 8.36% to $6.0 million in 2025, then fell by 17.99% to $4.9 million in 2026.
• Per Business Quant, the three latest MRVI Depreciation & Amortization (CF) figures stand at $4.9 million (Q1 2026), $6.0 million (Q4 2025), and $6.0 million (Q3 2025).